Lupin's South African subsidiary signs commercial agreement with Creso Pharma

Lupin announced that its subsidiary in South Africa, 'Pharma Dynamics' has signed a Commercial Agreement with Creso Pharma (Creso) for the hemp oil based cannaQIX. Creso affords Pharma Dynamics sole distribution rights of its organic, broad spectrum hemp oil nutraceutical, cannaQIXlQ, across South Africa, Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Angola, Mozambique and Uganda.

The cannaQIX range of products are cannabidiol (CBD) hemp oil-based nutraceut icals, which conta in full spectrum organic hemp oil extracts with CBD, vitamins and zinc, aiming to reduce stress and to support mental and nervous functions. Cannabidiol is one of many identified cannabinoids in cannabis plants and has been linked to improved anxiety, pain management, movement therapy and cognition.

The products are sugar free and contain no Tetrahydrocannabinol (THC) - the principal psychoactive constituent of cannabis.

The standardized, user-friendly strength and formulation allows precise dosage control, ensuring a rel iable and stable effect over several days. The cannaQIX range has been developed per Good Manufacturing Practice standards and is produced in Switzerland by Creso's partner, Swiss-based food and pharma development company, Domaco, Dr. med Aufdermaur AG (Domaco) to the highest Swiss quality with a "Swiss Made" label.

Powered by Capital Market - Live News